---
title: Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
nct_id: NCT04337203
overall_status: COMPLETED
phase: NA
sponsor: Wake Forest University Health Sciences
study_type: INTERVENTIONAL
primary_condition: Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04337203.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04337203"
ct_last_update_post_date: 2023-06-28
last_seen_at: "2026-05-12T07:02:25.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Shared Healthcare Actions and Reflections Electronic Systems in Survivorship

**Official Title:** SHARE-S Aim 3: Shared Healthcare Actions & Reflections Electronic Systems in Survivorship

**NCT ID:** [NCT04337203](https://clinicaltrials.gov/study/NCT04337203)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Wake Forest University Health Sciences
- **Collaborators:** National Cancer Institute (NCI)
- **Conditions:** Cancer, Survivorship, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- **Start Date:** 2020-09-08
- **Completion Date:** 2022-05-31
- **CT.gov Last Update:** 2023-06-28

## Brief Summary

The primary purpose of this study is conduct a pilot study testing the study protocols, implementation program, and mixed-methods data collection.

## Detailed Description

Primary Objectives:

• To evaluate how successfully SHARE-S can be implemented into clinical care as characterized by rates of enrollment. Investigators hypothesize \>30% of patients e-referred to SHARE-S will enroll.

Secondary Objectives:

* To assess additional implementation outcomes that evaluate preliminary implementation success (i.e., further assessment of adoption, acceptability, appropriateness, further assessment of feasibility, and fidelity).
* To describe service outcome variability to inform future studies. Investigators will assess service outcomes relevant to Commission on Cancer requirements by reporting annual estimates for: (1) the estimated number of patients impacted by SHARE-S; (2) the cancer sites impacted by SHARE-S; and the (3) resources/processes utilized to enhance each of the chosen services if barriers were encountered. We will also assess safety and perceived patient-centeredness of care.
* To describe patient health outcome variability to inform future studies (i.e., social role, physical functioning, anxiety, depression, fatigue, sleep disturbance, pain, cancer-specific quality of life, health behaviors, patient autonomy, self-efficacy for managing cancer, engagement with the survivorship care plan document, and satisfaction with care).
* To evaluate the Implementation Program we will assess key milestones and processes for this pilot study of the Implementation Stage measured at the clinic level.
* To qualitatively assess implementation barriers and facilitators using semi-structured interviews that will be audio-recorded.
* To examine how study results vary by cancer type.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 100 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Adults ≥18 years of age
* Documented or planned cancer survivorship visit
* Have a texting enabled telephone
* Cognitively able to complete study procedures as judged by the study team
* Able to understand, read and write English

Children under the age of 18 with cancer will be excluded due to the potentially different self-management support intervention needs of this population that will likely include parental involvement. Results from this research may inform future studies in children with cancer under 18 who should be researched separately.

Exclusion Criteria

\- Declined participation in the study
```

## Arms

- **SHARE-S** (EXPERIMENTAL) — Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.

## Interventions

- **SHARE-S Implementation Program** (BEHAVIORAL) — The program consists of three components: An electronic referral among clinical teams for potential participants, patient engagement with survivorship care planning guidelines through self-management/health coaching. One coaching call before a clinic visit (60 minutes) and two coaching calls after the clinic visit (30 minutes each). Participants will also receive automated, tailored text messages (daily for three weeks before and after a clinic visit for a total of six weeks).

## Primary Outcomes

- **Number of Patients Enrolled Out of Those Electronically Referred** _(time frame: 1 year, 8 months)_ — Using a 95% confidence interval (CI) to determine the range of estimates that are consistent with our data. Investigators will track the number of new patients seen in the Survivorship Clinic, and the percent who agree to be referred to SHARE-S.

## Secondary Outcomes

- **Adoption - Number of Electronically Referred Patients - Those Possible [Based on Chart Review]** _(time frame: 1 year, 8 months)_
- **Acceptability of Intervention Measure** _(time frame: Up to 30 days after the final intervention session.)_
- **Appropriateness of Intervention Measure** _(time frame: Up to 30 days after the final intervention session.)_
- **Number of Participants Enrolled Per Month** _(time frame: 1 year, 8 months)_
- **Feasibility of Intervention Measure** _(time frame: Up to 30 days after the final intervention session.)_
- **Retention Rates** _(time frame: Up to 30 days after the final intervention session.)_
- **Number of Participants Adhering to Text Responses** _(time frame: 1 year, 8 months)_
- **Participant Adherence to Coaching Sessions** _(time frame: 1 year, 8 months)_
- **Length of Coaching Sessions** _(time frame: Up to 30 days after the final intervention session.)_
- **Number of Coaching Sessions Completed** _(time frame: 1 year, 8 months)_
- **Total Number of Patients Enrolled** _(time frame: 1 year, 8 months)_
- **Frequency of Adverse Events** _(time frame: Up to 30 days after the final intervention session.)_
- **HEAL Patient-Provider Connection** _(time frame: Up to 30 days after the final intervention session.)_
- **Patient-Reported Health Outcomes PROMIS Profile 29** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **36-Item Short Form Survey (SF-36)** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Cancer-specific Quality of Life in Adult Cancer Survivors (QLACS) Questionnaire** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Index of Autonomous Functioning - Self Congruence Subscale Only** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Self-Efficacy to Manage Chronic Disease Questionnaire** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Engagement With the Survivorship Care Plan** _(time frame: 1 year, 8 months)_
- **Satisfaction of Care** _(time frame: Up to 30 days after the final intervention session.)_
- **Health Behaviors Questionnaire - Tobacco Use** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Health Behaviors Questionnaire - Alcohol Use Disorder** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Health Behaviors Questionnaire - Physical Activity** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Health Behaviors Questionnaire - Fruit and Vegetable Intake** _(time frame: At baseline and up to 30 days after the final intervention session.)_
- **Health Behaviors Questionnaire - Mindfulness Practice** _(time frame: At baseline and up to 30 days after the final intervention session.)_

## Locations (1)

- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

## Recent Field Changes (last 30 days)

- `locations.wake forest baptist comprehensive cancer center|winston-salem|north carolina|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04337203.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04337203*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*